This cluster groups 2 independently calculated changes: Cash & equivalents increased 43.6%; Operating cash flow increased 49.3%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTBiohaven Ltd.'s latest supported as-filed period reports net income of -$129.3M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 43.6%; Operating cash flow increased 49.3%.
2 evidence-backed componentsCurrent assets changed -40.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BHVN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001935979-26-000093SEC ↗10-QOct 29, 2026Period Sep 30, 20260001935979-26-000092SEC ↗8-KOct 22, 2026Period Oct 22, 20260001935979-26-000083SEC ↗8-KOct 15, 2026Period Oct 8, 20260001935979-26-000080SEC ↗4Sep 17, 2026Period Sep 15, 20260001704186-26-000006SEC ↗8-KSep 10, 2026Period Sep 4, 20260001935979-26-000077SEC ↗8-KAug 26, 2026Period Aug 26, 20260001935979-26-000072SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 15, 2026Filed Sep 17, 2026 | Gentile KimberlySVP, Clinical Operations | Grant Or AwardIndirect | 1,000 | $0 | $0 | Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 | Mehta KishanDirector | Grant Or AwardDirect | 68,693 | $0 | $0 | Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 | Bailey GregoryDirector | Grant Or AwardDirect | 68,693 | $0 | $0 | Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 | Heffernan Michael ThomasDirector | Grant Or AwardDirect | 68,693 | $0 | $0 | Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Total assets changed -35.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed -38.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Shares outstanding changed +42.8% from the comparable as-filed period. The change ranks at the 71th percentile of 7 prior comparable changes.
Current assets changed -37.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed -32.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed +26.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001935979-26-000067| Antonijevic IrinaDirector |
| Grant Or AwardDirect |
| 68,693 |
| $0 |
| $0 |
| Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 | CHILDS JOHN WDirector | Grant Or AwardDirect | 68,693 | $0 | $0 | Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 | HUGIN ROBERT JDirector | Grant Or AwardDirect | 68,693 | $0 | $0 | Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 | GREGORY JULIA PDirector | Grant Or AwardDirect | 68,693 | $0 | $0 | Form 4 ↗ |
| Mar 17, 2026Filed Mar 19, 2026 | Mehta KishanDirector | GiftDirect | 17,342 | $0 | $0 | Form 4 ↗ |
| Mar 17, 2026Filed Mar 19, 2026 | Mehta KishanDirector | GiftIndirect | 17,342 | $0 | $0 | Form 4 ↗ |
| Feb 27, 2026Filed Mar 3, 2026 | Buten MatthewChief Financial Officer | Grant Or AwardDirect | 175,000 | $0 | $0 | Form 4 ↗ |
| Feb 27, 2026Filed Mar 3, 2026 | Gentile KimberlySVP, Clinical Operations | Grant Or AwardDirect | 175,000 | $0 | $0 | Form 4 ↗ |
| Feb 27, 2026Filed Mar 3, 2026 | Clark George C.VP, Chief Accounting Officer | Grant Or AwardDirect | 50,000 | $0 | $0 | Form 4 ↗ |
| Mar 4, 2025Filed Mar 9, 2026 | CHILDS JOHN WDirector | Open Market PurchaseIndirect · amended | 28,400 | $30 | $864,115 | Form 4 ↗ |